Related Experiment Video
Updated: Jan 16, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
SCH79797, an Antiplatelet Agent, Alleviates Restenosis by Inducing Apoptosis via p53-Mediated Mitochondrial
Ting-Lin Yen1,2, Kun-Jing Hong1, Jing-Shiun Jan2
1Department of Medical Research, Cathay General Hospital, 280 Renai Rd. Sec.4, Taipei City 10630, Taiwan.
Insights
SCH79797 effectively reduces coronary in-stent restenosis (ISR) by inducing vascular smooth muscle cell apoptosis via a p53-mediated mitochondrial pathway. This novel dual-action therapeutic candidate also exhibits antithrombotic effects, paving the way for improved localized drug-eluting strategies.
Area of Science:
- Interventional Cardiology
- Vascular Biology
- Molecular Medicine
Background:
- Coronary in-stent restenosis (ISR) remains a significant challenge in interventional cardiology despite advancements in drug-eluting stents (DESs) and drug-eluting balloons (DEBs).
- Existing treatments struggle to fully address ISR, leading to increased patient morbidity and suboptimal long-term outcomes.
- Novel therapeutic strategies targeting ISR mechanisms are crucial for improving revascularization success.
Purpose of the Study:
- To investigate the potential of SCH79797 as a novel therapeutic agent for treating coronary in-stent restenosis (ISR).
- To elucidate the specific mechanisms by which SCH79797 induces apoptosis in vascular smooth muscle cells (VSMCs).
- To evaluate the in vivo efficacy of SCH79797 in reducing restenosis and thrombosis.
Main Methods:
- Utilized A10 cells for in vitro apoptosis studies and a rat common carotid artery balloon injury model for in vivo evaluation.
- Investigated SCH79797's effects on VSMC apoptosis, including pathways like JNK/c-Jun, p53, and mitochondrial signaling (Bax/Bcl-2 ratio, mitochondrial membrane potential).
- Assessed SCH79797's efficacy in reducing arterial restenosis and thrombosis following balloon injury in vivo.
Main Results:
- SCH79797 induced VSMC apoptosis through upregulation of JNK/c-Jun and p53, and modulated mitochondrial pathways (increased Bax/Bcl-2, altered membrane potential).
- The apoptotic effects of SCH79797 were independent of its protease-activated receptor-1 (PAR-1) antagonist activity, differentiating it from vorapaxar.
- In vivo, SCH79797 significantly reduced both restenosis and thrombosis in the rat carotid artery model.
Conclusions:
- SCH79797 directly induces VSMC apoptosis via a p53-mediated mitochondrial pathway, offering a novel mechanism for ISR treatment.
- SCH79797 presents a unique dual-action profile, combining apoptotic induction with antithrombotic effects, unlike traditional anti-proliferative agents.
- These findings support the development of localized drug-eluting strategies using SCH79797 (e.g., in DES or DEBs) for effective ISR prevention with potentially reduced systemic side effects.
Introduction:
In the field of interventional cardiology, coronary in-stent restenosis (ISR) continues to present a clinical hurdle, even with the progress made in stent design and pharmacological interventions. While drug-eluting stents (DESs) and drug-eluting balloons (DEBs) have markedly decreased the occurrence of ISR when compared to bare-metal stents, the condition persists as a complication in revascularization, contributing to increased patient morbidity and challenging long-term treatment outcomes. Thus, a deeper understanding of ISR mechanisms and the development of novel therapeutic approaches are crucial for improving patient outcomes.
Methods:
In this study, we utilized the A10 cell as an in vitro model and induced common carotid artery balloon dilation injury in Sprague-Dawley rats as an animal model to explore the potential clinical applications of SCH79797, particularly in the treatment of ISR.
Results:
SCH79797, a protease-activated receptor-1 antagonist, induced apoptosis of smooth muscle cells through various pathways. SCH79797 promoted apoptosis via JNK/c-Jun and p53 upregulation in the cytosol. We also observed an increased Bax/Bcl-2 ratio in mitochondria, p53 translocation to mitochondria, and changes in the mitochondrial membrane potential to mitochondrial membrane permeabilization. Our comparative analysis with vorapaxar revealed the apoptotic effects of SCH79797 to be independent of its PAR-1 antagonist activity. Furthermore, SCH79797 administration significantly reduced common carotid artery restenosis and thrombosis following balloon injury in vivo.
Discussion:
Our study has been the first to demonstrate SCH79797 to directly induce VSMC apoptosis via the p53-mediated mitochondrial pathway, providing a novel mechanistic insight into ISR treatment. Unlike traditional anti-proliferative agents used in DESs, SCH79797 uniquely combines apoptotic induction with antithrombotic effects, making it a dual-action therapeutic candidate. This research study has laid the groundwork for localized drug-eluting strategies that can leverage SCH79797's properties to prevent ISR more effectively while minimizing systemic side effects.
Conclusion:
Our findings have established SCH79797 as a promising candidate for reducing ISR through apoptosis modulation. By leveraging the p53-mediated mitochondrial apoptotic pathway, SCH79797 may provide a groundbreaking approach to reducing restenosis. These findings could offer significant implications for the future development of targeted drug-eluting strategies by locally delivering SCH79797 in a controlled manner using DES or DEB, presenting SCH79797 as a transformative candidate in interventional cardiology.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:27Coronary Artery Disease V: Interprofessional Care